Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2015-02-04 Major Shareholding Noti…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2015-02-04 English
8-KEXECUTIVECOMP
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content specifically details the appointment of a new President and Chief Operating Officer, Matthew W. Foehr, and changes in executive compensation. It includes biographical and compensation information about executives and mentions the Compensation Committee's decisions. This fits the description of announcements related to changes in the company's board of directors or senior management. There is no financial statement or detailed financial report included, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement or voting results announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5212 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2015-02-02 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-01-09 English
Regulatory Filings 2015
Regulatory Filings
2015-01-08 English
Regulatory Filings 2015
Regulatory Filings
2015-01-08 English
PRIMARY DOCUMENT
Director's Dealing
2015-01-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.